Purchase this article with an account.
R. Guthoff, K. Hennemann, W. Goebel, W. Schrader; Bevacizumab versus Triamcinolone for Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Pair-Matched Analysis. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2700.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To retrospectively analyze the outcome of patients with macular edema (ME) secondary to retinal vein occlusion treated by bevacizumab vs. triamcinolone.
5 patients treated with bevacizumab for argon laser-refractory ME after branch vein occlusion (BVO) were matched pairwise with 5 TA treated patients in regard to initially comparable VA and central retinal thickness (CRT) (BVO group). In the same way 18 patients with ME after central vein occlusion (CVO) were retrospectively pair matched in regard to comparable VA and CRT (CVO group). VA and CRT, measured by OCT, at first and last presentation were evaluated. Previously vitrectomized eyes were not included.
In the BVO group, mean initial VA (LogMAR) of bevacizumab patients (mean age 70±4 years) and TA patients (mean age 65±11 years) was 0.12±0.06 and 0.13±0.07, respectively. Initial CRT of bevacizumab patients and TA patients was 599±117 µm and 575±83µm, respectively. Final VA of bevacizumab patients after 1 injection was 0.36±0.15 at the end of a mean follow up of 2±0.6 months. Final VA of TA patients after a mean of 1.2 injections was 0.26±0.2 at the end of a mean follow up of 8±5.7 months. CRT decreased by 348±55µm after bevacizumab und by 297±412µm after TA.In the CVO group, mean initial VA (LogMAR) of bevacizumab patients (mean age 63±11 years) and TA patients (mean age 67±6 years) was 0.15±0.12 and 0.18±0.12, respectively. Initial CRT of bevacizumab patients and TA patients was 586±226 µm and 593±233µm, respectively. Final VA of bevacizumab patients after a mean of 1 injection was 0.27±0.24 at the end of a mean follow up of 4±2 months. Final VA of TA patients after a mean of 1.4 injections was 0.16±0.2 at the end of a mean follow up of 11±8 months. CRT decreased by 143±158µm after bevacizumab and by 154±159µm after TA.
Bevacizumab was more efficient to increase VA in both BVO and CVO than TA. TA was ineffective concerning VA of CVO patients while macular morphology improved more than after bevacizumab.
This PDF is available to Subscribers Only